Sigrid Ring

2.5k total citations · 1 hit paper
21 papers, 1.9k citations indexed

About

Sigrid Ring is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Sigrid Ring has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Sigrid Ring's work include Melanoma and MAPK Pathways (8 papers), Immunotherapy and Immune Responses (6 papers) and Cutaneous Melanoma Detection and Management (6 papers). Sigrid Ring is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), Immunotherapy and Immune Responses (6 papers) and Cutaneous Melanoma Detection and Management (6 papers). Sigrid Ring collaborates with scholars based in United States, Australia and Brazil. Sigrid Ring's co-authors include Sewa S. Legha, Agop Y. Bedikian, Carl Plager, Omar Eton, Antônio C. Buzaid, Robert S. Benjamin, Nikolaos G. Papadopoulos, Julie A. Ellerhorst, S S Legha and Edgardo Rivera and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Sigrid Ring

21 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

2002 504 citations Sewa S. Legha, Sigrid Ring et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sigrid Ring United States	14	1.4k	812	592	234	164	21	1.9k
Ruth Oratz United States	24	1.2k 0.8×	708 0.9×	759 1.3×	36 0.2×	190 1.2×	78	1.9k
Pia Vihinen Finland	21	959 0.7×	802 1.0×	210 0.4×	69 0.3×	142 0.9×	55	2.0k
B Leyland-Jones United States	16	847 0.6×	418 0.5×	76 0.1×	351 1.5×	197 1.2×	42	1.7k
Sari H. Enschede United States	19	1.2k 0.8×	2.1k 2.6×	717 1.2×	63 0.3×	381 2.3×	46	4.0k
Christopher A. Slapak United States	23	1.3k 0.9×	1.1k 1.4×	194 0.3×	59 0.3×	247 1.5×	42	2.3k
Lon Smith United States	17	1.8k 1.3×	1.1k 1.4×	197 0.3×	112 0.5×	429 2.6×	35	2.5k
Caterina Ieranò Italy	20	917 0.6×	546 0.7×	462 0.8×	46 0.2×	119 0.7×	34	1.4k
Sagun Parakh Australia	19	892 0.6×	389 0.5×	249 0.4×	65 0.3×	306 1.9×	79	1.5k
T Ohnuma United States	16	812 0.6×	554 0.7×	87 0.1×	354 1.5×	202 1.2×	40	1.7k
Becker Hewes United States	18	1000 0.7×	617 0.8×	624 1.1×	89 0.4×	393 2.4×	34	2.0k

Countries citing papers authored by Sigrid Ring

Since Specialization

Citations

This map shows the geographic impact of Sigrid Ring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sigrid Ring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sigrid Ring more than expected).

Fields of papers citing papers by Sigrid Ring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sigrid Ring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sigrid Ring. The network helps show where Sigrid Ring may publish in the future.

Co-authorship network of co-authors of Sigrid Ring

This figure shows the co-authorship network connecting the top 25 collaborators of Sigrid Ring. A scholar is included among the top collaborators of Sigrid Ring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sigrid Ring. Sigrid Ring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Papadopoulos, Nicholas E., Agop Y. Bedikian, Sigrid Ring, et al.. (2009). Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. American Journal of Clinical Oncology. 32(5). 509–514. 14 indexed citations

Bedikian, Agop Y., Nikolaos G. Papadopoulos, Carl Plager, Omar Eton, & Sigrid Ring. (2003). Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Research. 13(3). 303–306. 57 indexed citations

Eton, Omar, Sewa S. Legha, Agop Y. Bedikian, et al.. (2002). Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial. Journal of Clinical Oncology. 20(8). 2045–2052. 257 indexed citations

Ellerhorst, Julie A., A. Y. Bedikian, Sigrid Ring, et al.. (1999). Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.. Oncology Reports. 6(5). 1097–9. 40 indexed citations

Legha, S S, Sigrid Ring, Omar Eton, et al.. (1998). Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.. Journal of Clinical Oncology. 16(5). 1752–1759. 221 indexed citations

Eton, Omar, S S Legha, Antônio C. Buzaid, et al.. (1998). Prognostic factors for survival of patients treated systemically for disseminated melanoma.. Journal of Clinical Oncology. 16(3). 1103–1111. 167 indexed citations

Buzaid, Antônio C., Agop Y. Bedikian, Omar Eton, et al.. (1998). Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Research. 8(6). 549–556. 62 indexed citations

Legha, Sewa S., Sigrid Ring, Omar Eton, et al.. (1997). Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.. PubMed. 3 Suppl 1. S9–15. 54 indexed citations

Legha, Sewa S., Sigrid Ring, Agop Y. Bedikian, et al.. (1996). Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Annals of Oncology. 7(8). 827–835. 141 indexed citations

10.

Legha, Sewa S., Sigrid Ring, Antônio C. Buzaid, & Merrick I. Ross. (1995). 18 Preoperative chemotherapy with cisplatin, vinblastine and dacarbazine (CVD) in patients with local-regional recurrence of melanoma (AJCC stage-HI). Melanoma Research. 5(6). 449–449. 2 indexed citations

11.

Buzaid, Antônio C., Elizabeth A. Grimm, Francis Ali‐Osman, et al.. (1994). Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results. Melanoma Research. 4(5). 327–330. 8 indexed citations

12.

Buzaid, Antônio C., Sewa S. Legha, Charles M. Balch, et al.. (1994). Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer. 74(9). 2476–2482. 10 indexed citations

13.

Legha, Sewa S., Sigrid Ring, Agop Y. Bedikian, et al.. (1993). Biochemotherapy using interleukin-2 + interferon alpha-2a (IFN) in combination with cisplatin (C), vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Melanoma Research. 3(1). 32–32. 4 indexed citations

14.

Legha, Sewa S., et al.. (1992). Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy. Cancer. 70(7). 2018–2020. 4 indexed citations

15.

Itoh, Kyogo, Kazuhiro Hayakawa, Sewa S. Legha, et al.. (1991). Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunology Immunotherapy. 33(4). 238–246. 10 indexed citations

16.

Legha, Sewa S., Sigrid Ring, Nikolaos G. Papadopoulos, Martin N. Raber, & Robert S. Benjamin. (1990). A phase II trial of taxol in metastatic melanoma. Cancer. 65(11). 2478–2481. 143 indexed citations

17.

Legha, Sewa S., Sigrid Ring, Nikolaos G. Papadopoulos, et al.. (1989). A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 64(10). 2024–2029. 136 indexed citations

18.

Legha, Sewa S., Nicholas Papadopoulos, Carl Plager, et al.. (1987). Clinical Evaluation of Recombinant Interferon Alfa-2A (Roferon-A) in Metastatic Melanoma Using Two Different Schedules. Journal of Clinical Oncology. 5(11). 1858–1858. 2 indexed citations

19.

Legha, Sewa S., Nicholas E. Papadopoulos, Carl Plager, et al.. (1987). Clinical evaluation of recombinant interferon alfa-2a (Roferon-A) in metastatic melanoma using two different schedules .. Journal of Clinical Oncology. 5(8). 1240–1246. 39 indexed citations

20.

Ring, Sigrid, et al.. (1987). Phase I clinical investigation of benzisoquinolinedione.. PubMed. 71(12). 1165–9. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact